Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Overview
Lisata Therapeutics Inc (LSTA) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies designed to treat advanced solid tumors and other significant diseases. Leveraging cutting-edge peptide technology, the company is focused on addressing major unmet medical needs in oncology by enhancing the delivery of anti-cancer drugs through a novel uptake pathway. Keywords such as clinical-stage pharmaceutical, solid tumors, and oncology are essential in understanding the company's core focus.
Innovative Technologies and Product Pipeline
At the heart of Lisata Therapeutics' robust research and development efforts is its investigational product, certepetide. This cyclic iRGD peptide is engineered to activate a unique uptake pathway, enabling co-administered or tethered anti-cancer drugs to selectively penetrate and accumulate within solid tumors. By effectively modifying the tumor microenvironment and reducing its immunosuppressive characteristics, certepetide offers an advanced method to enhance the efficacy of conventional chemotherapy, immunotherapies, and RNA-based therapeutics.
The company employs its proprietary CendR Platform technology as a foundation for its research, supporting multiple clinical trials across various tumor types. With studies evaluating the safety, tolerability, and therapeutic potential of certepetide in combination with standard-of-care regimens, Lisata is actively exploring opportunities in both first-line and second-line therapeutic settings. This strategic approach facilitates a comprehensive evaluation of the product across a range of cancers, including pancreatic, cholangiocarcinoma, glioblastoma, colon, and melanoma.
Research & Development and Strategic Collaborations
Lisata Therapeutics stands out for its commitment to extensive research and collaboration. The company has established noteworthy partnerships with academic institutions, biotechnology firms, and diagnostic innovators to accelerate the clinical development of its product candidates. These collaborations not only reflect the company’s expertise in translational medicine but also support the integration of novel diagnostic strategies, such as advanced imaging and molecular assays, to monitor therapeutic response accurately.
Through its diversified clinical trial portfolio, Lisata is engaged in both early and pivotal phase studies, evaluating the role of certepetide in enhancing drug delivery and achieving better patient outcomes. The company’s strategic initiatives have been structured to address the challenges inherent in targeting advanced solid tumors and to provide detailed insights into the mechanism of drug-tumor interactions.
Market Position and Significance
Within the competitive landscape of oncology therapeutics, Lisata Therapeutics is recognized for its innovative approach to drug delivery and tumor targeting. The company's scientific strategy, rooted in the modification of the tumor microenvironment and enhanced drug penetration, offers substantial differentiation from other therapeutic modalities. This focus on leveraging peptide technology to improve the performance of co-administered anti-cancer agents positions Lisata as an important contributor to the evolving cancer treatment paradigm.
Lisata’s comprehensive approach—spanning drug development, strategic partnerships, and collaborative research—underscores its commitment to advancing treatment options for patients with difficult-to-treat malignancies. The scientific rigor applied in its clinical studies and the transparent dissemination of clinical milestones underscore the company’s dedication to improving our understanding of tumor biology and therapeutic innovation.
Clinical Trials and Future Directions
While Lisata is known for its robust pipeline and forward-thinking clinical programs, the company remains focused on providing critical data from its ongoing investigations. The breadth of its trial portfolio not only includes evaluations in solid tumor oncology but also extends into exploring non-oncology applications, reflecting the versatility of its technology platform. Each study is designed to yield actionable insights regarding therapeutic activity and safety, thereby reinforcing the scientific competence and credibility of the company.
In summary, Lisata Therapeutics exemplifies a modern biopharmaceutical company that combines advanced peptide technology with a strategic, research-driven approach to address some of the most challenging therapeutic needs in oncology today. Its comprehensive and methodical R&D efforts, bolstered by strategic collaborations and a clear focus on enhancing drug delivery, make it a significant entity within the field of targeted cancer therapies.
BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, a clinical-stage pharmaceutical company, announced that CEO David J. Mazzo, PhD, will present at three upcoming conferences:
- LSX World Congress: May 3-4, 2023 in London. Dr. Mazzo's presentation will be on May 3 at 11:15 a.m. British Summer Time.
- Sidoti Micro-Cap Conference: May 10-11, 2023, virtual. Dr. Mazzo will present on May 10 at 10:00 a.m. Eastern Time.
- Bio€quity Europe 2023: May 14-16, 2023 in Dublin. Dr. Mazzo's presentation is set for May 15 at 1:41 p.m. Irish Standard Time.
Lisata develops innovative therapies for advanced solid tumors and is advancing its lead candidate, LSTA1, designed to enhance anti-cancer drug delivery while minimizing effects on normal tissues. The company is actively exploring treatment modalities for various solid tumors.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has secured $2.2 million in non-dilutive funding through New Jersey's Technology Business Tax Certificate Transfer Program. This funding allows Lisata to convert state net operating losses into working capital, which will enhance their clinical development initiatives. Over the past four years, Lisata has received nearly $18 million through this program. The company is focused on advancing its therapeutic candidate, LSTA1, designed to improve the delivery of anti-cancer drugs to solid tumors. LSTA1 has shown promising results in clinical trials, particularly for pancreatic cancer, and may enhance the efficacy of various cancer treatments while minimizing side effects on normal tissues.
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors, will participate in the Sequire Investor Summit from April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico. CEO David J. Mazzo will present a company overview on April 25 at 3:00 PM. The event aims to connect emerging companies with investors.
Lisata's lead investigational product, LSTA1, targets novel uptake pathways for anti-cancer drugs, enhancing their delivery to tumors while sparing normal tissues. It has shown favorable safety and activity in clinical trials for pancreatic cancer, and has potential for various treatment modalities, including immunotherapies. The company continues to gather data to support LSTA1's effectiveness against a range of solid tumors.
Lisata Therapeutics (LSTA) has initiated the iLSTA Trial, a pivotal study evaluating its investigational drug LSTA1 in combination with standard chemotherapy and immunotherapy for locally advanced pancreatic ductal adenocarcinoma (PDAC). Conducted in Australia, this trial aims to treat 30 patients and assess safety and pharmacodynamics. WARPNINE will manage the trial, providing funding and recruitment support, while Lisata supplies the drug and regulatory assistance. LSTA1 is designed to enhance drug delivery to tumors, potentially improving treatment outcomes for patients with this challenging cancer. Positive early results could signify a major breakthrough in pancreatic cancer therapy.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) reported its 2022 financial results and a business update, highlighting significant clinical developments in its drug pipeline. The lead candidate, LSTA1, is advancing in global studies for solid tumors, showing promise in enhancing delivery of anti-cancer drugs. HONEDRA® is in pre-consultation for registration in Japan, while XOWNA® faces enrollment challenges due to COVID-19 impacts. Financially, the company saw a 26% decrease in R&D expenses for the year, totaling $13.1 million, and experienced net losses of $54.2 million. As of December 31, 2022, Lisata had $69.2 million in cash, projected to sustain operations through mid-2025.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced it will report its financial results for Q4 and FY 2022 on March 30, 2023, post-market. The conference call will start at 4:30 p.m. ET, with a new registration process for participants. Lisata is a clinical-stage company focused on developing innovative therapies for advanced solid tumors. Its lead product, LSTA1, aims to enhance the delivery of anti-cancer drugs to tumors while sparing normal tissues, showing promising results in pancreatic cancer trials. Lisata continues to explore LSTA1 for various solid tumors, alongside its autologous CD34+ cell therapy technology.
Lisata Therapeutics (Nasdaq: LSTA) announced its participation in two major investor conferences. The first event is the 2023 BIO CEO & Investor Conference in New York, scheduled for February 6-9, 2023, where CEO David J. Mazzo will present on February 7. The second event is Biocom California’s 13th Annual Global Life Science Partnering & Investor Conference in La Jolla, taking place from February 28 to March 2, 2023, with President David S. Slack presenting on March 1. These conferences will include one-on-one investor meetings. Lisata focuses on innovative therapies for advanced tumors, with its lead candidate, LSTA1, showing promise in enhancing drug delivery for pancreatic cancer.
Lisata Therapeutics (LSTA) reported its Q3 2022 financial results, showing significant advancements in its clinical pipeline post-merger. The company is actively conducting Phase 1b/2 studies of LSTA1 in China, Australia/New Zealand, and the U.S., with preliminary data expected in late 2023 and 2024. Research and development expenses decreased to $3.4 million, while net losses rose to $37.4 million. The company has approximately $75.5 million in cash, cash equivalents, and securities, positioning it for future trials and strategic partnerships.
BASKING RIDGE, N.J., Nov. 7, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced participation in key upcoming events. These include the RNA at the Bench and Bedside III from November 8-10 in Carlsbad, CA, with David Slack attending one-on-one meetings. They will also present at the Inv€$tival Showcase 2022 on November 14 in London, with David J. Mazzo presenting a corporate overview at 2:30 p.m. GMT. Lastly, management will engage in one-on-one meetings at the Jefferies London Healthcare Conference from November 15-17, also in London.
FAQ
What is the current stock price of Lisata Therapeutics (LSTA)?
What is the market cap of Lisata Therapeutics (LSTA)?
What is the primary focus of Lisata Therapeutics?
How does Lisata's investigational product, certepetide, work?
What technology platform supports Lisata's research and development?
In which types of cancer is Lisata focusing its clinical trials?
What is the significance of Lisata's strategic collaborations?
How do Lisata's solutions differentiate it from other oncology therapeutics?
Are there any non-oncology applications being explored by Lisata?
What role do clinical trials play in Lisata's development strategy?
